Detalles de la búsqueda
1.
Reproductive Safety Issues of Novel Small Molecules for the Treatment of Inflammatory Bowel Disease: A Systematic Review.
J Clin Med
; 13(1)2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38202041
2.
Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13).
BMJ Open Gastroenterol
; 10(1)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36813298
3.
Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project.
Frontline Gastroenterol
; 14(6): 497-504, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37854782
4.
Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.
J Clin Med
; 11(19)2022 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36233537
5.
Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Aliment Pharmacol Ther
; 56(5): 783-793, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768996
6.
The role of biologics in the treatment of patients with inflammatory bowel disease.
Br J Hosp Med (Lond)
; 79(12): 686-693, 2018 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30526103
7.
Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
Aliment Pharmacol Ther
; 53(2): 346-347, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368516
8.
Pregnancy and inflammatory bowel disease: Do we provide enough patient education? A British study of 1324 women.
World J Gastroenterol
; 22(36): 8219-25, 2016 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27688664
Resultados
1 -
8
de 8
1
Próxima >
>>